![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
| Item Type: | Article |
|---|---|
| Title: | First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A - results of a retrospective analysis |
| Creators Name: | Pouyiourou, M. and Meyer, A. and Stroux, A. and Viardot, A. and La Rosée, P. and Maschmeyer, G. and Kämpfe, D. and Kahl, C. and Vucinic, V. and Monecke, A. and Hirt, C. and Weber, T. and Meissner, J. and Witzens-Harig, M. and Böttcher, S. and Schmalenberg, H. and Marks, R. and Prange-Krex, G. and Kroschinsky, F. and Hauf, E. and Keller, U. and Koch, K. and Klapper, W. and Herold, M. and Scholz, C.W. |
| Abstract: | Based on centroblast frequency, follicular lymphoma (FL) is subdivided into grades 1-2, 3A, and 3B. Grade FL3A frequently coexists with FL1-2 (FL1-2-3A). Based on clinical trials, FL1-2 is treated with rituximab (R) or obinutuzumab plus bendamustine (B) or CHOP, while FL3B is treated with R-CHOP. In contrast, there are little data guiding therapy in FL3A. We present a retrospective, multicenter analysis of 95 FL3A or FL1-2-3A and 203 FL1-2 patients treated with R-CHOP or R-B first-line. R-CHOP facilitated a higher response rate (95% versus 76%) and longer overall survival (OS) (3-year OS 89% versus 73%, P = 0.008) in FL3A or FL1-2-3A, whereas the difference in progression-free survival (PFS) did not reach statistical significance. While transformation rates into aggressive lymphoma were similar between both groups, there were more additional malignancies after R-B compared with R-CHOP (6 versus 2 cases). In FL1-2, R-B achieved a higher 3-year PFS (79% versus 47%, P < 0.01), while there was no significant difference regarding OS or transformation. With the limitations of a retrospective analysis, these results suggest a benefit for R-CHOP over R-B in FL3A or FL1-2-3A. Confirmatory data from prospective clinical trials are needed. |
| Keywords: | Follicular Lymphoma, Grade 3A, Rituximab, Bendamustine, CHOP |
| Source: | Annals of Hematology |
| ISSN: | 0939-5555 |
| Publisher: | Springer |
| Volume: | 99 |
| Number: | 12 |
| Page Range: | 2821-2829 |
| Date: | December 2020 |
| Official Publication: | https://doi.org/10.1007/s00277-020-04171-7 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
